Approaching eradication of highly active antiretroviral therapy-persistent human immunodeficiency virus type 1 reservoirs with immune activation therapy

Clinical Infectious Diseases

Volumn 35, Issue 12, 2002, Pages 1520-1526

  Kulkosky, Joseph ^a   Pomerantz, Roger J ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 2; OKT 3; PROSTRATIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIRUS RNA;

ADULT RESPIRATORY DISTRESS SYNDROME; ARTICLE; ASEPTIC MENINGITIS; DENDRITIC CELL; DRUG MECHANISM; ERADICATION THERAPY; GENETIC HETEROGENEITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOTENSION; IMMUNE RESPONSE; IMMUNOTHERAPY; LATENT VIRUS INFECTION; MACROPHAGE; MONOCYTE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; PROVIRUS; REMISSION; T LYMPHOCYTE SUBPOPULATION; VIRUS LOAD; VIRUS REPLICATION; VIRUS RESISTANCE;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HIV INFECTIONS; HIV-1; HUMANS; IMMUNITY;

EID: 0037115244     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/344959     Document Type: Article

References (50)

1. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997; 337:734-9.
2. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853-60.
3. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trial Group 320 Study Team. N Engl J Med 1997;337:725-33.
4. Schrager LK, D'Souza MP. Cellular and anatomical reservoirs of HIV-1 in patients receiving potent antiretroviral combination therapy. JAMA 1998; 280:67-71.
5. Perelson AS, Essunger P, Cao Y, et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 1997; 387:188-91.
6. Cavert W, Notermans DW, Staskus K, et al. Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. Science 1997;276:960-4.
7. Zhang L, Ramratnan B, Tenner-Racz K, et al. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med 1999;340:1605-13.
8. - T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 1999; 5:512-7.
9. Wong JK, Hezarech M, Gunthard HF, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997; 278:1291-5.
10. Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active anti-retroviral therapy. Science 1997;278:1295-300.
11. Chun TW, Stuyver L, Mizell SB, et al. Presence of an inducible HIV-1 latent reservoir during highly active anti-retroviral therapy. Proc Natl Acad Sci USA 1997;94:13193-7.
12. Harrigan RP, Whaley M, Montaner JSG. Rate of HIV-1 RNA rebound upon stopping antiretroviral therapy. AIDS 1999; 13:F59-62.
13. Montaner JSG, Harris M, Mo T, Harrigan PR. Rebound of plasma HIV viral load following prolonged suppression with combination therapy. AIDS 1998; 12:1398-9.
14. Pierson T, Hoffman TL, Blankson J, et al. Characterization of chemokine receptor utilization of viruses in the latent reservoir for human immunodeficiency virus type 1. J Virol 2000; 74:7824-33.
15. Sonza S, Mutimer HP, Oelrichs R, et al. Monocytes harbour replication-competent non-latent HIV-1 in patients on highly active antiretroviral therapy. AIDS 2001; 15:17-22.
16. + T cells expanded with inactivated-virus-pulsed dendritic cells. J Virol 2001; 75:8949-56.
17. Pomerantz RJ. Residual HIV-1 infection during antiretroviral therapy: The challenge of viral persistence. AIDS 2001; 15:1201-11.
18. Huisman MT, Smit JW, Schinkel AH. Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors. AIDS 2000; 14:237-42.
19. Chun T-W, Davey RT Jr, Ostrowski M, et al. Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy. Nat Med 2000; 6:757-61.
20. Davey RT Jr, Bhat N, Yoder C, et al. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc Natl Acad Sci USA 1999;96:15109-14.
21. Kovacs JA, Imamichi H, Vogel S, et al. Effects of intermittent interleukin-2 therapy on plasma and tissue human immunodeficiency virus levels and quasi-species expression. J Infect Dis 2000; 182:1063-9.
22. Karlsson AC, Birk M, Lindback S, Gaines H, Mittler JE, Sonnerborg A. Initiation of therapy during primary HIV type 1 infection results in a continuous decay of proviral DNA and a highly restricted viral evolution. AIDS Res Hum Retroviruses 2001; 17:409-16.
23. Zhang L, Chung C, Hu B-S, et al. Genetic characterization of rebounding HIV-1 after cessation of highly active antiretroviral therapy. J Clin Invest 2000; 106:839-45.
24. Imamichi H, Crandall KA, Natarajan V, et al. Human immunodeficiency virus type 1 quasi species that rebound after discontinuation of highly active antiretroviral therapy are similar to the viral quasi species present before initiation of therapy. J Infect Dis 2001; 183:36-50.
25. Havlir DV, Gilbert PB, Bennett K, et al. Effects of treatment intensification with hydroxyurea in HIV-infected patients with virologic suppression. AIDS 2001; 15:1379-88.
26. Lori F, Malykh A, Cara A, et al. Hydroxyurea as an inhibitor of human immunodeficiency virus-type I replication. Science 1994; 266:801-5.
27. Chapius AG, Paolo Rizzardi G, D'Agostino C, et al. Effects of mycophenolic acid on human immunodeficiency virus infection in vitro and in vivo. Nat Med 2000;6:762-8.
28. Vila J, Nugier F, Bargues G, et al. Absence of viral rebound after treatment of HIV-infected patients with didanosine and hydroxycarbamide. Lancet 1997;350(9078):635-6.
29. + cells in HIV-1-infected patients receiving highly active anti-retroviral therapy. Nat Med 1999; 5:651-5.
30. Prins JM, Jurriaans S, van Praag RME, et al. Immuno-activation with anti-CD3 and recombinant human IL-2 in HIV-I-infected patients on potent antiretroviral therapy. AIDS 1999; 13:2405-10.
31. Fraser C, Ferguson NM, Ghani AC, et al. Reduction of the HIV-1-infected T-cell reservoir by immune activation treatment is dose-dependent and restricted by the potency of antiretroviral drugs. AIDS 2000; 14:659-69.
32. Lafeuillade A, Poggi C, Chadapaud S, et al. Pilot study of a combination of highly active antiretroviral therapy and cytokines to induce HIV-1 remission. J Acquir Immune Defic Syndr 2001;26:44-55.
33. Ellenhorn JD, Woodle ES, Ghobreal I, Thistlewaite JR, Bluestone JA. Activation of human T cells in vivo following treatment of transplantation recipients with OKT3. Transplantation 1990;50:608-12.
34. Meuer SC, Hussey RE, Cantrell DA, et al. Triggering of the T3-Ti antigen-receptor complex results in clonal T-cell proliferation through an interleukin 2-dependent autocrine pathway. Proc Natl Acad Sci USA 1984; 81:1509-13.
35. Sell S. Immunology, Immunopathology and Immunity, 6th Ed. Washington, DC: American Society for Microbiology, Press, 2001.
36. + T cells using a combination of cytokines. J Exp Med 1998; 188:83-91.
37. - T cell depletion. J Clin Immunol 2001; 21:218-26.
38. Kulkosky J, Culnan DM, Roman J, et al. Prostratin: Activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART. Blood 2001;98:3006-15.
39. Gulakowski RJ, McMahon JB, Buckhiet RW Jr, Gustafson KR, Boyd MR. Antireplicative and anticytopathic activities of prostratin, a non-tumor-promoting phorbol ester, against human immunodeficiency virus (HIV). Antiviral Res 1997;33:87-93.
40. Lambotte O, Taoufik Y, de Goer MG, Wallon C, Goujard C, Delfraissy JF. Detection of infectious HIV in circulating monocytes from patients on prolonged highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2000; 23:114-9.
41. + monocytes and its potential role as a source of virus in patients on highly active antiretroviral therapy. J Virol 2002;76:707-16.
42. Korin YD, Brooks DG, Brown S, Korotzer A, Zack JA. Effects of prostratin on T-cell activation and human immunodeficiency virus latency. J Virol 2002; 76:8118-23.
43. Kulkosky J, Nunnari G, Otero M, et al. Intensification and stimulation therapy for human immunodeficiency virus type 1 reservoirs in infected individuals receiving virally suppressive highly active antiretroviral therapy. J Infect Dis 2002; 186:1403-11.
44. Rosenberg ES, Altfeld M, Poon SH, et al. Immune control of HIV-1 after early treatment of acute infection. Nature 2000; 407:523-6.
45. Carcelain G, Tubiana R, Samri A, et al. Transient mobilization of human immunodeficiency virus (HIV)-specific CD4 T-helper cells fails to control virus rebounds during intermittent antiretroviral therapy in chronic HIV type 1 infection. J Virol 2001; 75:234-41.
46. Hel Z, Venzon D, Poudyal M, et al. Viremia control following anti-retroviral treatment and therapeutic immunization during primary SIV251 infection of macaques. Nat Med 2000;6:1140-6.
47. Berger EA, Moss B, Pastan I. Reconsidering targeted toxins to eliminate HW infection: You gotta have HAART. Proc Natl Acad Sci USA 1998; 95:11511-3.
48. Saavedra-Lozano J, McCoig C, Xu J, et al. An anti-CD45RO immunotoxin kills latently infected human immunodeficiency virus (HIV) CD4 T cells in the blood of HIV-positive persons. J Infect Dis 2002; 185: 306-14.
49. + T cells induces expansion of peripheral T cells and decreased CCR5 expression in HIV infection. Nat Med 2002; 8:47-53.
50. Pomerantz RJ. Reservoirs of human immunodeficiency virus type 1: The main obstacles to viral eradication. Glin Infect Dis 2002;34:91-7.